Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Relapse after HSCT 2021
#IMS23 | @OcioEnrique of @HUnivValdecilla shares safety and efficacy results from the ANCHOR trial.
Watch the interview here:
👉 👈
#TrialUpdate #CTSM #MultipleMyeloma #MMSM #HemOnc #ImmunoOnc @Myeloma_Society
Efficacy and safety results from the ANCHOR trial
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, shares efficacy and safety results ...
ow.ly
#ASH23 is next week and we’re looking forward to interviewing KOLs in #HemOnc.
Unable to attend on 9th-12th December? We'll be bringing you exclusive insights into this year’s meeting on http://VJHemOnc.com!
@ASH_hematology #MDSsm #LymSM #LeuSM #DLBCL
Post-ASH Virtual Highlights Series, feat presentations & discussions on selected abstracts from 65th #ASH23 Annual Meeting 💻🩸
Webinars led by: @Daver_Leukemia, Bijal Shah, @Dr_AmerZeidan, @harrisoncn1, @mvmateos & John Gribben
REGISTRATION OPEN👉https://www.vjhemonc.com/feature/post-ash-2023-highlights/
🎥 Lisa Leypoldt of @UKEHamburg comments on the findings of the Phase II GMMG-CONCEPT trial of Isa-KRd in high-risk NDMM.
Watch here:
👉
#TrialUpdate #CTSM #MultipleMyeloma #MMSM #IMS23 #HemOnc #ImmunoOnc @Myeloma_Society
GMMG-CONCEPT trial: Isa-KRd in high-risk newly diagnosed multiple myeloma
In this video, Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, shares results from the Phase ...
ow.ly
#COSTEM23 | Riccardo Saccardi of @AOUCareggi gives an insight into the impact various conditioning regimens have on the outcomes of patients with autoimmune diseases.
Watch here:
👉 👈
#HemOnc @COSTEMCongress
The impact of conditioning regimens on the outcomes of patients with autoimmune diseases
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses the impact of various conditioning regimens...
ow.ly
Relapse after HSCT 2021
#IMS23 | @OcioEnrique of @HUnivValdecilla shares safety and efficacy results from the ANCHOR trial.
Watch the interview here:
👉 👈
#TrialUpdate #CTSM #MultipleMyeloma #MMSM #HemOnc #ImmunoOnc @Myeloma_Society
Efficacy and safety results from the ANCHOR trial
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, shares efficacy and safety results ...
ow.ly
#ASH23 is next week and we’re looking forward to interviewing KOLs in #HemOnc.
Unable to attend on 9th-12th December? We'll be bringing you exclusive insights into this year’s meeting on http://VJHemOnc.com!
@ASH_hematology #MDSsm #LymSM #LeuSM #DLBCL
Post-ASH Virtual Highlights Series, feat presentations & discussions on selected abstracts from 65th #ASH23 Annual Meeting 💻🩸
Webinars led by: @Daver_Leukemia, Bijal Shah, @Dr_AmerZeidan, @harrisoncn1, @mvmateos & John Gribben
REGISTRATION OPEN👉https://www.vjhemonc.com/feature/post-ash-2023-highlights/
🎥 Lisa Leypoldt of @UKEHamburg comments on the findings of the Phase II GMMG-CONCEPT trial of Isa-KRd in high-risk NDMM.
Watch here:
👉
#TrialUpdate #CTSM #MultipleMyeloma #MMSM #IMS23 #HemOnc #ImmunoOnc @Myeloma_Society
GMMG-CONCEPT trial: Isa-KRd in high-risk newly diagnosed multiple myeloma
In this video, Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, shares results from the Phase ...
ow.ly
#COSTEM23 | Riccardo Saccardi of @AOUCareggi gives an insight into the impact various conditioning regimens have on the outcomes of patients with autoimmune diseases.
Watch here:
👉 👈
#HemOnc @COSTEMCongress
The impact of conditioning regimens on the outcomes of patients with autoimmune diseases
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses the impact of various conditioning regimens...
ow.ly
